18:30 , May 11, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse...
16:48 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
07:00 , Aug 1, 2016 |  BC Extra  |  Financial News

Bioniz raises $13M in series A round

Bioniz Therapeutics Inc. (Irvine, Calif.) raised $13 million in a series A round co-led by the Takeda Ventures unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and David Pyott, the former chairman and CEO of Allergan...